metoprolol trial summary

Acute myocardial infarction

Immediate beta-blockers: 4 trials - MIAMI Trial Research Group - Von Essen - Waagstein - TIMI IIB

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.89 [0.70 1.12]	p=1.00	0	7219	3	MIAMI Trial Research Group ,Von Essen ,TIMI IIB,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Practololormetoprolol vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	1.18 [0.02 61.13]	p=1.00	0	83	1	Waagstein ,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

Long term beta-blockers: 5 trials - Hjalmarson - LIT Research Group - Manger Cats - Rehnqvist - Salathia

Metoprolol vs placebo

No demonstrated result

suggested reinfarction by 38% (not demonstrated)

suggested All cause death by 21% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiac event (fatal and non fatal )	no data
reinfarction	0.62 [0.43 0.88]	p=0.04	0	1696	2	Hjalmarson ,Rehnqvist ,
Sudden death	0.68 [0.42 1.09]	p=1.00	0	3195	2	LIT Research Group ,Salathia ,
cardiovascular events	no data
Cardiovascular death	0.93 [0.68 1.28]	p=1.00	0	2395	1	LIT Research Group ,
myocardial infarction (fatal and non fatal)	no data
cardiac death	0.93 [0.72 1.21]	p=1.00	0	3195	2	LIT Research Group ,Salathia ,
All cause death	0.79 [0.65 0.96]	p=0.04	0	5408	5	Hjalmarson ,LIT Research Group ,Manger Cats ,Rehnqvist ,Salathia ,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Atrial fibrillation

Maintaining sinus rhythm after cardioversion: 1 trials - Kuhlkamp

metoprolol vs placebo

No demonstrated result

suggested Pro-arrhythmia by 3000% (not demonstrated)

suggested Adverse events leading to treatment discontinuation by 233% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death or hospitalization for cardiac causes	no data
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Atrial fibrillation recurrence	0.91 [0.59 1.39]	p=1.00	0	394	1	Kuhlkamp,
Cardiac nonarrhythmic death	no data
Cardiac arrhythmic death	no data
Vascular noncardiac death	no data
hospitalization for AF	no data
hospitalisation for heart failure	no data
Pro-arrhythmia	31.00 [1.84 521.87]	p=0.04	0	394	1	Kuhlkamp,
All cause death	7.00 [0.36 136.43]	p=1.00	0	394	1	Kuhlkamp,
non cardiovascular death	no data
Adverse events leading to treatment discontinuation	3.33 [1.31 8.49]	p=0.04	0	394	1	Kuhlkamp,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Diabetes type 2

Patients with or without hypertension: 1 trials - MERIT-HF

metoprolol vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	1.30 [0.67 2.52]	p=1.00	0	985	1	MERIT-HF,
stroke (fatal and non fatal)	no data
microvascular events	no data
Non fatal MI	no data
All cause death	0.81 [0.55 1.21]	p=1.00	0	985	1	MERIT-HF,
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Heart failure

All type of heart failure: 6 trials - MDC (Waagstein) - MERIT-HF - Engelmeier - Fisher - Eichhorn - RESOLVD

metoprolol vs placebo

No demonstrated result

suggested Sudden death by 40% (not demonstrated)

suggested Cardiovascular death by 37% (not demonstrated)

suggested All cause death by 31% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Death from any cause or hospitalization for any reason	0.77 [0.49 1.20]	p=1.00	0	383	1	MDC (Waagstein),
Sudden death	0.60 [0.45 0.80]	p=0.04	0	3991	1	MERIT-HF,
NYHA class improvement	1.41 [0.94 2.11]	p=1.00	0	482	4	MDC (Waagstein),Engelmeier,Fisher,Eichhorn,
cardiovascular events	no data
Cardiovascular death	0.63 [0.50 0.80]	p=0.04	0	3991	1	MERIT-HF,
Coronary event	no data
Coronary death	no data
hospitalisation for heart failure	0.64 [0.41 1.02]	p=1.00	0	482	4	MDC (Waagstein),Engelmeier,Fisher,Eichhorn,
All cause death	0.69 [0.56 0.84]	p=0.04	0	4899	6	MDC (Waagstein),MERIT-HF,Engelmeier,Fisher,Eichhorn,RESOLVD,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

Elderly patients: 1 trials - BEST (elderly subgroup)

Metoprolol vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.91 [0.75 1.11]	p=1.00	0	-18	1	BEST (elderly subgroup),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Metoprolol beta-blockers

CGP2175 - CGP 2175 - CGP-2175 - BetalocAstra - Betaloc Astra - Betaloc-Astra - Betaloc - Seloken - Metoprolol Tartrate - Lopressor - H 9326 - H 93 26 - H 93-26 - Spesikor - Spesicor - Betalok - BelocDuriles - Beloc Duriles - Beloc-Duriles - Metoprolol

Acute myocardial infarction

Atrial fibrillation

Diabetes type 2

Heart failure